

ASX Release May 15, 2025

## Epsilon Healthcare Limited announces issue of loan notes

### HIGHLIGHTS

- ◆ **Subject to participation, up to \$1,000,000 to be raised from the issue of loan notes to fund working capital as EPN advances operations & diversification activities.**
- ◆ **The funding structure is designed to minimise dilution to existing shareholders and is complemented by recent cost-reduction initiatives implemented by EPN during Q4 2024 and Q1 2025.**

**Commenting on the issue of the loan notes, EPN's chairman Mr. Alan Beasley said:** “We are pleased to have commenced this funding in a challenging market. The funds raised will allow EPN to continue the ongoing work of investing in the business and undertake activities necessary to lift the suspension of trading of the Company's shares. The structure of the loan note raising is intended to provide minimal dilution to existing shareholders and reflects our commitment to protecting shareholder value.”

Epsilon Healthcare Limited (ASX: EPN) (**EPN**) has commenced the process of raising up to \$1,000,000 through the issue of loan notes (**Notes**) to sophisticated, experienced or professional investors (**Noteholders**). The Notes will be progressively issued in tranches and will be redeemed (with interest) by EPN on 30 June 2025. Subject to obtaining shareholder approval at a future general meeting of EPN, the Notes have the ability to be converted into fully paid ordinary EPN shares at the election of the Noteholder (in lieu of being redeemed by EPN). Funds received from the Notes will be used by EPN to continue diversification and service expansion activities, working capital and new product offerings into EPN's manufacturing facility. The terms of the Notes are summarised as follows:

<b>Face Value</b>	\$0.02 per Note
<b>Number of Notes issued to date</b>	16,750,000
<b>Maximum amount of funds to be raised</b>	\$1,000,000
<b>Maximum number of Notes to be issued</b>	50,000,000
<b>Interest rate</b>	10% per annum (accruing daily and calculated on the Face Value) paid in arrears by EPN on the Redemption Date or the date that the Note is converted into a fully paid ordinary EPN share
<b>Redemption Date</b>	30 June 2025 (or such earlier date as nominated by EPN)
<b>Conversion rights</b>	Subject to EPN obtaining shareholder approval, each Note can be converted into one fully paid ordinary EPN share (in lieu of being redeemed by EPN)

This announcement has been approved by the full board of EPN

Alan Beasley  
Chairman

**EPSILON HEALTHCARE LIMITED**

E: [corporate@epsilonhealthcare.com.au](mailto:corporate@epsilonhealthcare.com.au)

For further information, please contact:

Peter Giannopoulos  
Managing Director and Group Chief Executive  
Officer

**EPSILON HEALTHCARE LIMITED**

E: [corporate@epsilonhealthcare.com.au](mailto:corporate@epsilonhealthcare.com.au)



Epsilon Healthcare Limited (ASX: EPN) – [epsilonhealthcare.com.au](http://epsilonhealthcare.com.au)

Epsilon Healthcare Limited (**ASX: EPN**) is an Australian based, globally active healthcare organisation. EPN operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacture & pharmacy dispensing and information services.

